Immunosuppressive Potential of Mesenchymal Stem Cells in Medicine

Adusumilli Pramod Kumar ¹, Jeesa George ¹

¹ Department of Pharmacy Practice, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Gnanagangothri Campus, Bangalore-560054, India.

Abstract

Immunosuppressive drugs are substances that suppress or reduce the strength of the body's immune system. They are often used to manage conditions where an overactive immune response leads to tissue damage or disease progression. Mesenchymal Stem Cells (MSCs) have garnered significant attention in research due to their multifaceted immunological properties, presenting them as potential therapeutic candidates for a range of disorders, including autoimmune diseases and tumors. Initially recognized for their ability to suppress T lymphocytes, recent studies have highlighted MSCs' impact on various immune cell types, T cells, B cells, natural killer (NK) cells, dendritic cells (DCs), macrophages, and neutrophils, underscoring their complex role in immune regulation and tolerance development. MSCs primarily suppress the immune system by inhibiting T cell proliferation through the release of substances such as TGF-β, HGF, PGE2, IL-10, HLA-G5, and IDO, promoting the generation of regulatory T cells (Tregs) that further dampen immune reactions. Furthermore, MSCs influence the function of DCs by impeding their development and maturation processes, while also enhancing the production of inflammatory molecules like IL-10. Similarly, MSCs hinder the proliferation of B cells and their antibody production, particularly in inflammatory contexts. Thus, immunosuppressive potential of MSCs holds significant promise for therapeutic applications.

Keywords: Immunosuppression, MSC, Medicine, Immunomodulation, Immune cells. 

References

[1]    Y. Hussain y H. Khan, «Immunosuppressive Drugs», Encycl. Infect. Immun., pp. 726-740, 2022, doi: 10.1016/B978-0-12-818731-9.00068-9.
[2]    M. Suthanthiran, R. E. Morris, y T. B. Strom, «Immunosuppressants: Cellular and molecular mechanisms of action», Am. J. Kidney Dis., vol. 28, n.o 2, pp. 159-172, ago. 1996, doi: 10.1016/S0272-6386(96)90297-8.
[3]    D. D. Kanatoula, E. Bodner, K. Ghoreschi, K. Meier, y F. Solimani, «Non-biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases», JDDG J. Dtsch. Dermatol. Ges., vol. 22, n.o 3, pp. 400-421, 2024, doi: 10.1111/ddg.15270.
[4]    M. E. Bernardo, F. Locatelli, y W. E. Fibbe, «Mesenchymal stromal cells», Ann. N. Y. Acad. Sci., vol. 1176, pp. 101-117, sep. 2009, doi: 10.1111/j.1749-6632.2009.04607.x.
[5]    N. Song, M. Scholtemeijer, y K. Shah, «Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic potential», Trends Pharmacol. Sci., vol. 41, n.o 9, pp. 653-664, sep. 2020, doi: 10.1016/j.tips.2020.06.009.
[6]    M. Krampera et al., «Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide», Blood, vol. 101, n.o 9, pp. 3722-3729, may 2003, doi: 10.1182/blood-2002-07-2104.
[7]    H. Afkhami, G. Mahmoudvand, A. Fakouri, A. Shadab, M. Mahjoor, y T. Komeili Movahhed, «New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons», Front. Cell Dev. Biol., vol. 11, p. 1255697, oct. 2023, doi: 10.3389/fcell.2023.1255697.
[8]    G. O’Malley et al., «Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?», Oncotarget, vol. 7, n.o 37, pp. 60752-60774, ago. 2016, doi: 10.18632/oncotarget.11354.
[9]    N. Negi y M. D. Griffin, «Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance», Stem Cells Dayt. Ohio, vol. 38, n.o 5, pp. 596-605, may 2020, doi: 10.1002/stem.3151.
[10]    D. M. Darlan, A. Raga, A. M. Muhar, A. Putra, y I. Alif, «Mesenchymal Stem Cells Suppress Dendritic Cells and Modulate Proinflammatory Milieu Through Interleukin-10 Expression in Peripheral Blood Mononuclear Cells of Human Systemic Lupus Erythematosus», Acta Inform. Medica, vol. 31, n.o 1, pp. 20-25, mar. 2023, doi: 10.5455/aim.2023.31.20-25.
[11]    N. Luque-Campos et al., «The Macrophage Response Is Driven by Mesenchymal Stem Cell-Mediated Metabolic Reprogramming», Front. Immunol., vol. 12, p. 624746, jun. 2021, doi: 10.3389/fimmu.2021.624746.
[12]    A. Bartholomew et al., «Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo», Exp. Hematol., vol. 30, n.o 1, pp. 42-48, ene. 2002, doi: 10.1016/s0301-472x(01)00769-x.
[13]    M. Di Nicola et al., «Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli», Blood, vol. 99, n.o 10, pp. 3838-3843, may 2002, doi: 10.1182/blood.v99.10.3838.
[14]    F. Djouad et al., «Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals», Blood, vol. 102, n.o 10, pp. 3837-3844, nov. 2003, doi: 10.1182/blood-2003-04-1193.
[15]    S. Zheng et al., «Mesenchymal Stromal Cells Rapidly Suppress TCR Signaling-Mediated Cytokine Transcription in Activated T Cells Through the ICAM-1/CD43 Interaction», Front. Immunol., vol. 12, p. 609544, feb. 2021, doi: 10.3389/fimmu.2021.609544.
[16]    J. Plumas, L. Chaperot, M.-J. Richard, J.-P. Molens, J.-C. Bensa, y M.-C. Favrot, «Mesenchymal stem cells induce apoptosis of activated T cells», Leukemia, vol. 19, n.o 9, pp. 1597-1604, sep. 2005, doi: 10.1038/sj.leu.2403871.
[17]    P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, y M. Papamichail, «Interactions between human mesenchymal stem cells and natural killer cells», Stem Cells Dayt. Ohio, vol. 24, n.o 1, pp. 74-85, ene. 2006, doi: 10.1634/stemcells.2004-0359.
[18]    C. de V. Machado, P. D. da S. Telles, y I. L. O. Nascimento, «Immunological characteristics of mesenchymal stem cells», Rev. Bras. Hematol. E Hemoter., vol. 35, n.o 1, pp. 62-67, 2013, doi: 10.5581/1516-8484.20130017.
[19]    S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, y F. Dazzi, «Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells», Blood, vol. 105, n.o 7, pp. 2821-2827, abr. 2005, doi: 10.1182/blood-2004-09-3696.
[20]    A. Corcione et al., «Human mesenchymal stem cells modulate B-cell functions», Blood, vol. 107, n.o 1, pp. 367-372, ene. 2006, doi: 10.1182/blood-2005-07-2657.
[21]    X.-X. Jiang et al., «Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells», Blood, vol. 105, n.o 10, pp. 4120-4126, may 2005, doi: 10.1182/blood-2004-02-0586.
[22]    G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, y L. Moretta, «Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation», Blood, vol. 107, n.o 4, pp. 1484-1490, feb. 2006, doi: 10.1182/blood-2005-07-2775.
[23]    J. Tolar, K. Le Blanc, A. Keating, y B. R. Blazar, «Hitting the right spot with mesenchymal stromal cells (MSCs)», Stem Cells Dayt. Ohio, vol. 28, n.o 8, pp. 1446-1455, ago. 2010, doi: 10.1002/stem.459.
[24]    Y. Jiang et al., «Mesenchymal stem cell-derived exosomes can alleviate GVHD and preserve the GVL effect in allogeneic stem cell transplantation animal models», Front. Immunol., vol. 14, p. 1284936, 2023, doi: 10.3389/fimmu.2023.1284936.
[25]    O. N. Koç et al., «Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy», J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 18, n.o 2, pp. 307-316, ene. 2000, doi: 10.1200/JCO.2000.18.2.307.
[26]    M. E. Bernardo et al., «Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation», Bone Marrow Transplant., vol. 46, n.o 2, pp. 200-207, feb. 2011, doi: 10.1038/bmt.2010.87.
[27]    J. A. Snowden et al., «Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR», J. Rheumatol., vol. 31, n.o 3, pp. 482-488, mar. 2004.
[28]    J. Moore et al., «A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis», Arthritis Rheum., vol. 46, n.o 9, pp. 2301-2309, sep. 2002, doi: 10.1002/art.10495.
[29]    Ö. Satirer, J. C. Henes, M. Döring, T. Lesk, S. Benseler, y J. B. Kuemmerle-Deschner, «Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children», RMD Open, vol. 10, n.o 3, p. e004381, jul. 2024, doi: 10.1136/rmdopen-2024-004381.
[30]    S. Goklemez et al., «Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus», Rheumatol. Oxf. Engl., vol. 61, n.o 8, pp. 3317-3328, dic. 2021, doi: 10.1093/rheumatology/keab877.
[31]    E. J. Dozois et al., «Durable Response in Patients With Refractory Fistulizing Perianal Crohn’s Disease Using Autologous Mesenchymal Stem Cells on a Dissolvable Matrix: Results from the Phase I Stem Cell on Matrix Plug Trial», Dis. Colon Rectum, vol. 66, n.o 2, pp. 243-252, feb. 2023, doi: 10.1097/DCR.0000000000002579.
[32]    X.-X. Wan et al., «Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement», Front. Endocrinol., vol. 13, p. 859638, mar. 2022, doi: 10.3389/fendo.2022.859638.

 Publication

Article ID: A0601026 RA Preprint 

Received: 22/05/2024

Accepted: 10/06/2024

Published: 15/06/2024

DOI: 10.64307/allbiosolutionA0601026

Citations

Adusumilli Pramod Kumar et al.Immunosuppressive Potential of Mesenchymal Stem Cells in Medicine. Journal of Allbiosolution, 2024, 6(1):261-273

A. Pramod Kumar  et al. Immunosuppressive Potential of Mesenchymal Stem Cells in Medicine. Allbiosolution, 2024, 6(1):261-273

 

How many times this paper is cited?

Comparative Assessment of Filgrastim Bio-similars via vertical gel electrophoresis (SDS-PAGE) and HPLC

Priyanka Chaudhary ¹, Muthusamy Kalaivani ¹, Kashish Chaudhary ², Anubhuti Goyal ¹, Meenakshi Dahiya¹, Rajeev Singh Raghuvanshi ¹

¹ Department of Biologics, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Govt. India, Sector-23, Raj Nagar, Ghaziabad-201 002, India.

² Department of Biotechnology, Bennett University, India

Abstract

Background: Filgrastim bio-similar have emerged as cost-effective alternatives to the reference filgrastim, providing comparable efficacy and safety profiles. Objective: In this study, we aim to show physico-chemical similarity between filgrastim biosimilars using vertical gel electrophoresis & high-performance liquid chromatography. Materials & Methods: In the present study, we evaluate filgrastim biosimilars (grafeel, religrast, neukine, colstim, emigrast) via SDS-PAGE and HPLC thereby checking their molecular weights for similarity and their qualitative analysis. The same was compared with reference standard of filgrastim (Filgrastim, certified Reference Material). Results: In the scope of the data obtained, we found that the main band of filgrastim in filgrastim biosimilars has the same electrophoretic mobility as the reference standard under non-reduced circumstances in case of SDS-PAGE, the outcomes demonstrated that the position of the principal band in the electropherogram produced by the test solution and the principal band produced by the reference solution are similar. The retention time of the main peak obtained with the test solution and the peak obtained with the reference solution are similar. For HPLC, all the filgrastim biosimilars showed monomer peaks on the RP-HPLC chromatograms, which eluted at 12.4 minutes, matching the retention duration of the filgrastim reference standard. Conclusion: Filgrastim has transformed the management of neutropenia and has become an indispensable therapy in various clinical settings. The development and approval of filgrastim biosimilars have expanded treatment options and improved accessibility, offered cost-effective alternatives while maintained comparable safety and efficacy. .  

Keywords: Filgrastim, Bio-similar, Physicochemical, SDS-PAGE, HPLC.

References:

1.    Sekhon B S: Biopharmaceuticals: An overview, Thai J. pharm Sci. 2010; 34:1-19
2.    Subbiah, V. The next generation of evidence-based medicine. Nat Med 29, 2023; 49-58. 
3.    Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696-705.
4.    Kim H, Alten R, Avedano L et al The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs. 2020; 80:99-113
5.    Halim L A, Marquez M, Maas-Bakker R F et al, Quality comparison of biosimilar and copy filgrastim products with the innovator product; Pharm Res 2018;35:226
6.    Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)–what is the difference? Med Oncol. 1998;15(4):229–33
7.    Herman AC, Boone TC, Lu HS. Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. Pharma Biotech. 1996;9: 303–28
8.    Hollingshead LM, Goa KL. Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF). 1991; Drugs 42, 300–30 
9.    Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008; 42(3):277-8
10.    Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005; 23:197-223
11.    Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002;62 Suppl 1:65-78.
12.    Bendall L J, Bradstock K F, G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent, Cytokine & Growth Factor Reviews, 2014; 4: 25. 
13.    Awad M, Singh P, Hilas O. Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA. P T. 2017;42(1):19-23.
14.    Kraj L, Krawczyk-Lipiec J, Gorniewska J et al. Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia. Biomed Rep. 2017; 2:143-47.
15.    Meher BR, Balan S, Mohanty RR, Jena M, Das S. Biosimilars in India; Current Status and Future Perspectives. J Pharm Bioallied Sci. 2019;11(1):12-15
16.    Joshi D, Khursheed R, Gupta S et al Biosimilars in Oncology: Latest Trends and Regulatory Status. Pharmaceutics. 2022;14(12):2721
17.    Sörgel, Fritz L, Lauber HT. Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with Its Reference Product. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy.  2010;24: 347-57.
18.    Qureshi H, Veeresham C. and Srinivas C. Analytical Method Development and Validation of Filgrastim by UV and RP-UPLC Methods. American Journal of Analytical Chemistry 2021;12: 333-46.
19.    Hannah R, Eyers, Claire- Analysis of Post-translational Modifications by LC-MS/MS. Methods in molecular biology (Clifton, N.J.). 2010;658: 93-108.
20.    Jadaun GPS, Dixit S, Saklani V et al HPLC for Peptides and Proteins: Principles, Methods and Applications Pharm Methods. 2017; 8(1): 1-6
21.    Kirley TL, Norman AB. Unfolding of IgG domains detected by non-reducing SDS-PAGE. Biochem Biophys Res Commun. 2018;503(2):944-49.
22.    Mantovani M, Caruso C S, Antonio D F et al, Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen: a double blind, single dose, two period cross over trial Dove press 2017;166:90.
23.    Macedo M K, Romero-Diaz A J, Miranda Hernandez M P, Duran K M, Flores-ortiz L F, Rivero E M; Characterization and comparability of biosimilars: a filgrastim case of study and regulatory perspectives for Latin America; Electronic J Biotech. 2016; 19:63-69. 
24.    Skrlin A, Radic I, Vuletic M et al Comparison of physicochemical properties of filgrastim; Science Direct 2010; 5:557-66. 
25.    Cory.E. Muraco; a fast and reliable method for purity analysis of filgrastim; reporter US 34.2. 
26.    Rathore AS, Bhambure R. Establishing analytical comparability for “biosimilars”: filgrastim as a case study. Anal Bioanal Chem. 2014; 406: 6569–76.  
27.    Tekdemir B, Seckin Z, Kacar AI et al. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product. Pharm Res; 2020: 37:215
28.    Skrlin A, Radic I, Schwinke, D et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals: Journal of the International Association of Biological Standardization. 2010; 38:557-66.
29.    Sörgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. Bio Drugs. 2015; 29:123-31.

Publication

Article ID: O0601027 RA Preprint 

Received: 05/06/2024

Accepted: 19/06/2024

Published: 05/07/2024

DOI: 10.64307/allbiosolutionO0601027

Citations

P. Chaudhary et al. Comparative Assessment of Filgrastim Bio-similars via vertical gel electrophoresis (SDS-PAGE) and HPLC. Journal of Allbiosolution, 2024, 6(1):271-277

P. Chaudhary et al. Comparative Assessment of Filgrastim Bio-similars via vertical gel electrophoresis (SDS-PAGE) and HPLC. Allbiosolution, 2024, 6(1):271-277

 

How many times this paper is cited?